Prolia (Denosumab) Effect on 25-OH Vitamin D

Denosumab Does Not Directly Alter 25-OH Vitamin D Levels

Denosumab is a fully human monoclonal antibody that binds receptor activator of nuclear factor kappa-B ligand (RANKL). It does not interact with hepatic 25-hydroxylase or renal 1-alpha-hydroxylase, the two enzymes responsible for producing and activating vitamin D. No RCT has demonstrated a statistically significant direct change in serum 25-OH vitamin D attributable to denosumab alone.

The confusion arises because denosumab profoundly suppresses bone resorption, which shifts calcium and phosphate homeostasis. When osteoclast activity drops sharply after the first injection, the body depends more heavily on intestinal calcium absorption to maintain serum calcium. That absorption requires adequate 1,25-dihydroxyvitamin D, which in turn requires sufficient 25-OH vitamin D substrate. If 25-OH vitamin D is already low, the compensatory pathway fails, and symptomatic hypocalcemia can develop within days to weeks of injection 1.

In the FREEDOM trial (N=7,868), investigators required all participants to receive calcium (≥1 to 000 mg) and vitamin D (≥400 IU) supplementation, which kept 25-OH vitamin D levels stable in both the denosumab and placebo arms 1. A secondary analysis of FREEDOM extension data through 10 years showed no systematic drift in 25-OH vitamin D among compliant patients 2.

The short version: denosumab does not touch vitamin D metabolism. It exposes existing vitamin D insufficiency by removing the skeletal calcium buffer that masks it.

Why Vitamin D Status Still Matters on Denosumab

Even though denosumab leaves 25-OH vitamin D untouched pharmacologically, low vitamin D status before injection is one of the strongest predictors of post-dose hypocalcemia. This section explains the physiology that connects the two.

Osteoclasts continuously release calcium from bone. This "resorptive calcium flux" provides roughly 500 mg of calcium per day to the extracellular fluid under normal turnover conditions. Denosumab suppresses osteoclast formation and survival within 12 hours of subcutaneous injection, cutting that resorptive flux by up to 85% within the first month, as measured by serum C-telopeptide (CTX) suppression 3.

With bone-derived calcium sharply reduced, the parathyroid glands respond by increasing parathyroid hormone (PTH) secretion. PTH signals the kidneys to convert more 25-OH vitamin D into active 1,25-dihydroxyvitamin D, which increases intestinal calcium absorption. This compensatory loop works well only if there is enough 25-OH vitamin D substrate to hydroxylate. A 25-OH vitamin D level below 20 ng/mL limits the substrate pool, and the compensation falls short.

A post-marketing pharmacovigilance analysis published in the Journal of Bone and Mineral Research found that 90% of severe hypocalcemia cases associated with denosumab occurred in patients with either pre-existing vitamin D deficiency (25-OH vitamin D <20 ng/mL) or chronic kidney disease (eGFR <30 mL/min) 4. The FDA prescribing information for Prolia explicitly states: "Pre-existing hypocalcemia must be corrected prior to initiating therapy with Prolia. Adequately supplement patients with calcium and vitamin D" 5.

The Endocrine Society's 2024 clinical practice guideline on vitamin D recommends maintaining serum 25-OH vitamin D at 30 ng/mL or above in patients receiving antiresorptive therapy, a threshold higher than the 20 ng/mL used for the general adult population 6.

Pre-Treatment Vitamin D Optimization Protocol

Before the first denosumab injection, clinicians should confirm that 25-OH vitamin D is at or above 30 ng/mL and serum calcium is within normal range. For patients who fall short, repletion should precede the injection, not accompany it.

The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guideline recommends a loading protocol of 50 to 000 IU ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) once weekly for 6 to 8 weeks when 25-OH vitamin D is below 20 ng/mL 7. For levels between 20 and 29 ng/mL, a daily dose of 2,000 to 4 to 000 IU cholecalciferol for 8 weeks typically brings levels above 30 ng/mL. Recheck 25-OH vitamin D at the end of the loading period.

Once levels are replete, maintenance dosing of 800 to 2 to 000 IU cholecalciferol daily keeps most patients above 30 ng/mL. Higher maintenance doses (up to 4 to 000 IU daily) may be needed in patients with obesity, malabsorption, or dark skin pigmentation, all factors that increase vitamin D requirements 6.

Calcium supplementation of 1,000 to 1 to 200 mg daily (diet plus supplements combined) is co-prescribed. Split doses improve absorption. Calcium citrate is preferred over calcium carbonate in patients taking proton pump inhibitors because it does not require gastric acid for dissolution.

A practical checklist before each denosumab injection:

1. 25-OH vitamin D ≥30 ng/mL
2. Albumin-corrected serum calcium within laboratory reference range
3. Patient confirms daily calcium + vitamin D intake
4. eGFR documented (renal patients need closer monitoring)

If 25-OH vitamin D is below 30 ng/mL at the scheduled injection visit, delay the injection and reload. "The cost of a four-week delay is negligible compared to the cost of managing symptomatic hypocalcemia requiring IV calcium infusion," notes the AACE guideline committee 7.

Monitoring 25-OH Vitamin D During Ongoing Therapy

Denosumab is administered as a 60 mg subcutaneous injection every 6 months. Each injection re-suppresses bone turnover, so the hypocalcemia risk window resets with every dose. Monitoring must continue, not just at baseline.

The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) recommends checking 25-OH vitamin D at least annually in patients on antiresorptive therapy, though many clinicians check it before every 6-month dose 8. A pre-dose lab draw timed 1 to 2 weeks before the scheduled injection gives adequate time to intervene if the level has dropped.

Seasonal variation in 25-OH vitamin D is well documented and clinically relevant. A population-based study in NHANES data showed that mean 25-OH vitamin D drops 5 to 8 ng/mL between summer peak and winter nadir across U.S. latitudes north of 37°N 9. A patient who was 32 ng/mL in July could be 24 ng/mL in January without any change in supplementation. Scheduling pre-dose labs before the winter and spring injections catches this drift.

Patients with chronic kidney disease (stages 3b through 5) require even tighter monitoring. In these patients, the conversion of 25-OH vitamin D to 1,25-dihydroxyvitamin D is impaired by reduced renal 1-alpha-hydroxylase activity, and denosumab-related hypocalcemia risk is substantially elevated. The 2017 KDIGO guideline update suggests checking 25-OH vitamin D every 3 months in CKD patients on antiresorptive therapy and correcting deficiency before each dose 10.

Magnitude of Calcium and PTH Shifts After Injection

While 25-OH vitamin D itself does not change meaningfully after a denosumab dose, other lab values shift in response to the sudden osteoclast suppression. Understanding these shifts helps clinicians interpret post-injection labs accurately.

In the FREEDOM trial, mean serum calcium declined by approximately 0.5 mg/dL (0.13 mmol/L) in the denosumab group versus 0.1 mg/dL in the placebo group during the first 10 days after injection 1. The nadir occurred between days 8 and 11. Most participants remained asymptomatic because calcium levels stayed above 8.0 mg/dL.

PTH rises in a mirror-image compensatory spike. A pharmacodynamic study by Amgen (denosumab's manufacturer) demonstrated a mean PTH increase of 15 to 20% above baseline within 2 weeks of injection, peaking around day 14 and returning to baseline by month 3 3. This PTH rise drives the increased demand for 25-OH vitamin D conversion.

Phosphate also dips transiently. A post hoc analysis of FREEDOM showed a mean serum phosphate decline of 0.15 mg/dL in the denosumab arm, consistent with PTH-mediated phosphaturia 2.

These shifts are subclinical in most patients with adequate vitamin D and calcium stores. They become dangerous when substrate is missing. A case series from Memorial Sloan Kettering (N=37 cancer patients receiving denosumab 120 mg monthly for bone metastases) found that 18.9% developed grade 3 or 4 hypocalcemia, and every patient with grade 4 events had a baseline 25-OH vitamin D below 15 ng/mL 11. The oncology dose is four times higher than the osteoporosis dose, but the principle is identical.

Special Populations: Who Needs More Aggressive Vitamin D Management

Certain patient groups are at higher risk for vitamin D insufficiency during denosumab therapy and need more frequent monitoring, higher supplement doses, or both.

Gastric bypass patients. Roux-en-Y and other malabsorptive bariatric procedures reduce vitamin D absorption by 30 to 50%. These patients often require 5,000 to 10 to 000 IU cholecalciferol daily or 50 to 000 IU weekly to maintain 25-OH vitamin D above 30 ng/mL 12. Quarterly 25-OH vitamin D checks are reasonable in this group.

Patients on glucocorticoids. Chronic prednisone use at ≥5 mg daily accelerates vitamin D catabolism through CYP3A4 induction and impairs intestinal calcium absorption independent of vitamin D status. The AACE recommends considering higher-dose vitamin D supplementation (2,000 to 4 to 000 IU daily) and checking levels every 3 to 6 months in steroid-treated patients receiving denosumab 7.

Elderly patients in institutional care. Nursing home residents have the highest prevalence of vitamin D deficiency in the United States. A cross-sectional study found that 60% of nursing home residents had 25-OH vitamin D below 20 ng/mL 13. For these patients, loading doses before denosumab initiation are almost always required.

Patients with CKD stage 4 or 5. As noted above, impaired 1-alpha-hydroxylation limits active vitamin D production. These patients may need calcitriol (0.25 to 0.5 mcg daily) in addition to cholecalciferol, and denosumab should be used with extreme caution. The KDIGO guideline notes that denosumab is not contraindicated in CKD but requires "close biochemical monitoring" 10.

What Happens to Vitamin D If Denosumab Is Discontinued

Stopping denosumab triggers a well-documented rebound in bone turnover. Osteoclast activity surges within 6 months of the last dose, and bone turnover markers (CTX, P1NP) can overshoot pre-treatment levels. This rebound is associated with rapid bone loss and increased vertebral fracture risk 14.

The rebound itself does not raise or lower 25-OH vitamin D. But the surge in osteoclast-mediated bone resorption releases a flood of calcium from the skeleton, temporarily raising serum calcium and suppressing PTH. The reduced PTH then decreases renal 1-alpha-hydroxylase activity, which may reduce the metabolic "demand" for 25-OH vitamin D substrate. Some clinicians observe a transient dip in 1,25-dihydroxyvitamin D during this period, though 25-OH vitamin D typically remains stable.

The practical concern on discontinuation is not vitamin D but fracture. The Bone Health and Osteoporosis Foundation recommends transitioning to a bisphosphonate (zoledronic acid 5 mg IV or alendronate 70 mg weekly) within 6 months of the last denosumab dose to prevent rebound bone loss 8. During the transition, maintaining 25-OH vitamin D ≥30 ng/mL remains important because bisphosphonates also require adequate vitamin D to work optimally and to minimize hypocalcemia risk with IV zoledronic acid.

Key Takeaway for Clinicians

Denosumab does not pharmacologically alter 25-OH vitamin D. It does, however, create a physiological environment where vitamin D insufficiency becomes acutely dangerous. Check 25-OH vitamin D before every injection, target ≥30 ng/mL, and reload aggressively if levels fall short. In CKD, post-bariatric, and glucocorticoid-treated patients, monitor quarterly and consider calcitriol or higher-dose cholecalciferol. Maintain supplementation through and beyond discontinuation, especially during the bisphosphonate transition window.